MELISSA CUMMINS: Open Payments
NPI 1275196651 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$438 in 22 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $817 · 2025 $438
Food & beverage: $438
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 5 | $123 |
| Axsome Therapeutics, Inc. | 3 | $61 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $56 |
| ABBVIE INC. | 3 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Sage Therapeutics, LLC | 1 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Corium, LLC | 2 | $20 |
| Luye Pharma (USA) Ltd. | 1 | $19 |
| Alkermes, Inc. | 1 | $16 |
Products named: HETLIOZ, Auvelity, CAPLYTA, VRAYLAR, TRINTELLIX, ZURZUVAE, ABILIFY MAINTENA, Azstarys.
Industry payments across MI — which companies pay providers there.
